Active	Status	Sponsor type	Region	Phase	Filter
11 Active 1 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Soares, Jair C
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD	Recruiting	3	255	US	Psilocybin, COMP360	COMPASS Pathways	Treatment Resistant Depression	02/25	02/26
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.	Terminated	3	83	Europe, Canada, Japan, US	SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo	Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.	Depressive Episodes, Bipolar I Depression	10/23	10/23
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression	Completed	2	197	Canada, US	Liafensine, Placebo	Denovo Biopharma LLC	Treatment Resistant Depression	02/24	03/24
NCT02046330: Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression	Active, not recruiting	N/A	16	US	Deep Brain Stimulation Model 3387 Model 3389, Medtronic Neuromodulation	The University of Texas Health Science Center, Houston, Medtronic	Major Depressive Disorder, Treatment Resistant Depression	04/27	04/27